Psyence Biomed to Present at the H.C. Wainwright 26th Annual Global Investment Conference, September 9th-11th, 2024
Psyence Biomedical (Nasdaq: PBM), a developer of nature-derived psilocybin-based therapeutics, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 9th-11th, 2024 at the Lotte New York Palace Hotel in New York City.
Key points:
- Psyence Biomed will present virtually and engage in one-on-one investor meetings
- The company's corporate presentation will be available on-demand from September 9th at 7:00 am (ET)
- Interested parties can schedule meetings with management by emailing ir@psyencebiomed.com
This participation provides an opportunity for Psyence Biomed to showcase its developments in psilocybin-based therapeutics to a global investment audience.
Psyence Biomedical (Nasdaq: PBM), sviluppatore di terapie a base di psilocibina derivata dalla natura, ha annunciato la sua partecipazione alla 26a Conferenza Globale Annuale sugli Investimenti H.C. Wainwright. L'evento si terrà dal 9 all'11 settembre 2024 presso il Lotte New York Palace Hotel di New York City.
Punti chiave:
- Psyence Biomed presenterà virtualmente e parteciperà a incontri individuali con gli investitori
- La presentazione aziendale sarà disponibile on-demand a partire dal 9 settembre alle 7:00 (ET)
- Le parti interessate possono programmare incontri con il management inviando un'email a ir@psyencebiomed.com
Questa partecipazione offre a Psyence Biomed l'opportunità di mostrare i suoi sviluppi nelle terapie a base di psilocibina a un pubblico globale di investitori.
Psyence Biomedical (Nasdaq: PBM), un desarrollador de terapias a base de psilocibina derivadas de la naturaleza, ha anunciado su participación en la 26ª Conferencia Global Anual de Inversiones H.C. Wainwright. El evento está programado para del 9 al 11 de septiembre de 2024 en el Lotte New York Palace Hotel en la ciudad de Nueva York.
Puntos clave:
- Psyence Biomed presentará virtualmente y participará en reuniones individuales con inversores
- La presentación corporativa estará disponible bajo demanda a partir del 9 de septiembre a las 7:00 am (ET)
- Las partes interesadas pueden programar reuniones con la dirección enviando un correo electrónico a ir@psyencebiomed.com
Esta participación proporciona a Psyence Biomed la oportunidad de mostrar sus desarrollos en terapias basadas en psilocibina a una audiencia global de inversores.
Psyence Biomedical (Nasdaq: PBM), 자연 유래의 실로시빈 기반 치료제를 개발하는 기업, H.C. Wainwright 제26회 연례 글로벌 투자 회의에 참여한다고 발표했습니다. 이 행사는 2024년 9월 9일부터 11일까지 뉴욕 시의 Lotte New York Palace Hotel에서 개최됩니다.
주요 사항:
- Psyence Biomed는 가상으로 발표하고 개인 투자자와의 1:1 회의에 참여할 예정입니다
- 회사의 기업 발표는 9월 9일 오전 7시(ET)부터 주문형으로 제공될 것입니다
- 관심 있는 분들은 ir@psyencebiomed.com으로 이메일을 보내 관리팀과 회의를 예약할 수 있습니다
이번 참여는 Psyence Biomed가 글로벌 투자자들에게 실로시빈 기반 치료제의 개발을 선보일 수 있는 기회를 제공합니다.
Psyence Biomedical (Nasdaq: PBM), un développeur de thérapies à base de psilocybine dérivée de la nature, a annoncé sa participation à la 26e Conférence Annuelle Mondiale des Investissements H.C. Wainwright. L'événement est prévu du 9 au 11 septembre 2024 à l'Hôtel Lotte New York Palace à New York.
Points clés :
- Psyence Biomed présentera virtuellement et participera à des réunions individuelles avec des investisseurs
- La présentation de l'entreprise sera disponible à la demande à partir du 9 septembre à 7h00 (ET)
- Les parties intéressées peuvent planifier des réunions avec la direction en envoyant un e-mail à ir@psyencebiomed.com
Cette participation offre à Psyence Biomed l'occasion de mettre en avant ses développements dans le domaine des thérapies à base de psilocybine auprès d'un public mondial d'investisseurs.
Psyence Biomedical (Nasdaq: PBM), ein Entwickler vonNaturstoffen abgeleiteten psilocybinbasierten Therapeutika, hat seine Teilnahme an der 26. Jahrestagung für globale Investitionen von H.C. Wainwright bekannt gegeben. Die Veranstaltung findet vom 9. bis 11. September 2024 im Lotte New York Palace Hotel in New York City statt.
Wichtige Punkte:
- Psyence Biomed wird virtuell präsentieren und an Einzelgesprächen mit Investoren teilnehmen
- Die Unternehmenspräsentation wird ab 9. September um 7:00 Uhr (ET) auf Abruf verfügbar sein
- Interessierte Parteien können Meetings mit dem Management vereinbaren, indem sie eine E-Mail an ir@psyencebiomed.com senden
Diese Teilnahme bietet Psyence Biomed die Gelegenheit, seine Entwicklungen im Bereich psilocybinbasierter Therapeutika einem globalen Investorenpublikum zu präsentieren.
- None.
- None.
NEW YORK, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”), a developer of nature-derived psilocybin-based therapeutics, today announced that it will present virtually and participate in one-on-one investor meetings at the H.C. Wainwright 26th Annual Global Investment Conference, taking place at the Lotte New York Palace Hotel in New York City from September 9th-11th, 2024 in New York.
Psyence Biomed’s corporate presentation will be available on-demand beginning on Monday, September 9th at 7:00 am (ET) via the conference platform.
If you would like to schedule a meeting with management, please reach out to Psyence Biomed directly via email: ir@psyencebiomed.com.
About Psyence Biomedical
Psyence Biomedical Ltd. (Nasdaq: PBM) is the world’s first life science biotechnology company focused on the development of botanical (nature-derived, or non-synthetic) psilocybin-based psychedelic medicine to be listed on Nasdaq. The name “Psyence” combines the words “psychedelics” and “science” to affirm Psyence Biomed’s commitment to an evidence-based approach to innovation as it works to develop safe and effective, nature-derived psychedelic therapeutics to treat a broad range of mental health disorders. Psyence is initially focused on mental health disorders in the context of Palliative Care.
Learn more at www.psyencebiomed.com and on LinkedIn.
Contact Information
Email: ir@psyencebiomed.com
Media Inquiries: media@psyencebiomed.com
General Information: info@psyencebiomed.com
Phone: +1 416-477-1708
Investor Contact:
Jeremy Feffer
Managing Director
LifeSci Advisors
jfeffer@lifesciadvisors.com
FAQ
When and where is Psyence Biomed (PBM) presenting at the H.C. Wainwright Global Investment Conference?
How can investors access Psyence Biomed's (PBM) corporate presentation at the conference?
What is the focus of Psyence Biomed's (PBM) research and development?
How can investors schedule meetings with Psyence Biomed (PBM) management during the conference?
